[Treatment with psychedelics : potential benefits in Parkinson's disease].

Psychedelics like psilocybin and LSD, acting through 5-HT2A receptors, rapidly and lastingly improve depression and anxiety by modulating neuroplasticity and brain connectivity. They may also help with addictions, post-traumatic stress, and obsessive-compulsive disorder. This article explores their potential in Parkinson's disease, both for treating depression, anxiety, and impulse control disorders and for neuroprotection. Psychedelics stimulate synaptogenesis, increase brain-derived neurotrophic factor, and have anti-inflammatory effects. However, clinical trials are needed to confirm safety and efficacy in Parkinson's disease.

Study at a glance

Abstract

Psychedelics, such as psilocybin and lysergic acid diethylamide, modulate neuroplasticity and brain connectivity via 5-HT2A receptors. Their efficacy has been demonstrated in depression and anxiety, where they are particularly interesting because of their rapid and long-lasting effect. They could also be beneficial for addictions, post-traumatic stress, and obsessive-compulsive disorder. This article explores their therapeutic potential in Parkinson's disease (PD), both symptomatically in PD depression, anxiety, and impulse control disorders, and in terms of neuroprotection. Psychedelics actually stimulate synaptogenesis, increase brain-derived neurotrophic factor, and exert anti-inflammatory effects. Although promising, these treatments require clinical trials to confirm their safety and efficacy in PD.